Adeno-Associated Virus-Based Gene Therapy for CNS Diseases

Human Gene Therapy

Volumn 27, Issue 7, 2016, Pages 478-496

  Hocquemiller, Michaël ^a   Giersch, Laura ^a   Audrain, Mickael ^b,c,d   Parker, Samantha ^a   Cartier, Nathalie ^c,d  

^a Lysogene SA   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID DELIVERY; CLINICAL RESEARCH; DEGENERATIVE DISEASE; EPILEPSY; HUMAN; HUNTINGTON CHOREA; INTRAPARENCHYMAL DELIVERY; INTRAVENOUS DELIVERY; LYSOSOME STORAGE DISEASE; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SPINAL MUSCULAR ATROPHY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADMINISTRATION AND DOSAGE; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; DEPENDOPARVOVIRUS; GENE THERAPY; GENE VECTOR; GENETICS;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS;

EID: 84987629880     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2016.087     Document Type: Review

References (217)

1. Choudhury SR, Hudry E, Maguire CA, et al. Viral vectors for therapy of neurologic diseases. Neu-ropharmacology 2016 (in press). DOI: 10.1016/j.neuropharm.2016.02.013
2. Hadaczek P, Eberling JL, Pivirotto P, et al. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 2010;18:1458-1461.
3. Mingozzi F, and High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011;12:341-355.
4. Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002;76:791-801.
5. Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004;10:302-317.
6. Davidson BL, Stein CS, Heth JA, et al. Re-combinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000;97:3428-3432.
7. Dodiya HB, Bjorklund T, Stansell J III, et al. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 2010;18:579-587.
8. Klein RL, Dayton RD, Tatom JB, et al. AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method. Mol Ther 2008;16:89-96.
9. Cearley CN, and Wolfe JH. Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 2006;13:528-537.
10. Furman JL, Sama DM, Gant JC, et al. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci 2012;32:16129-16140.
11. Lawlor PA, Bland RJ, Mouravlev A, et al. Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV se-rotypes isolated from nonhuman primates. Mol Ther 2009;17:1692-1702.
12. von Jonquieres G, Mersmann N, Klugmann CB, et al. Glial promoter selectivity following AAV-delivery to the immature brain. PLoS One 2013; 8:e65646.
13. Weller ML, Stone IM, Goss A, et al. Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuro-protection from moderate but not severe hypoxia-ischemia. Neuroscience 2008;155:1204-1211.
14. Simonato M, Bennett J, Boulis NM, et al. Progress in gene therapy for neurological disorders. Nat Rev Neurol 2013;9:277-291.
15. Leone P, Shera D, McPhee SW, et al. Long-term follow-up after gene therapy for canavan disease. Sci Transl Med 2012;4:165ra163.
16. Tardieu M, Zerah M, Husson B, et al. In-tracerebral administration of AAV rh.10 carrying human SGSH and SUMF1 cDNAs in children with MPSIIIA disease: results of a phase I/II trial. Hum Gene Ther 2014;25:506-516.
17. Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofusci-nosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther 2008;19:463-474.
18. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, et al. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther 2013;20:450-459.
19. Meyer K, Ferraiuolo L, Schmelzer L, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. Mol Ther 2015;23:477-487.
20. Tse LV, Moller-Tank S, and Asokan A. Strategies to circumvent humoral immunity to adeno-associated viral vectors. Expert Opin Biol Ther 2015;15:845-855.
21. Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pedi-atric disorders. Mol Ther 2011;19:1971-1980.
22. Foust KD, Nurre E, Montgomery CL, et al. In-travascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27:59-65.
23. Gray SJ, Matagne V, Bachaboina L, et al. Pre-clinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 2011;19:1058-1069.
24. Zhang H, Yang B, Mu X, et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 2011;19:1440-1448.
25. Cox TM, and Cachon-Gonzalez MB. The cellular pathology of lysosomal diseases. J Pathol 2012;226:241-254.
26. Fuller M, Meikle PJ, and Hopwood JJ. Epidemiology of lysosomal storage diseases: an overview. In: Fabry Disease: Perspectives from 5 Years of FOS. Mehta A, Beck M, Sunder-Plassmann G, eds. Oxford PharmaGenesis, Oxford. 2006; Chapter 2.
27. Bellettato CM, and Scarpa M. Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis 2010;33:347-362.
28. Fratantoni JC, Hall CW, and Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968;162: 570-572.
29. Chen F, Vitry S, Hocquemiller M, et al. a-L-Iduronidase transport in neurites. Mol Genet Metab 2006;87:349-358.
30. Leinekugel P, Michel S, Conzelmann E, et al. Quantitative correlation between the residual activity of b-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 1992;88:513-523.
31. Hemsley KM, and Hopwood JJ. Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis 2010;33:363-371.
32. Salegio EA, Samaranch L, Kells AP, et al. Axonal transport of adeno-associated viral vectors is serotype-dependent. Gene Ther 201;20:348-352.
33. Rosenberg JB, Sondhi D, Rubin DG, et al. Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates. Hum Gene Ther Clin Dev 2014;25:164-177.
34. Treleaven CM, Tamsett TJ, Bu J, et al. Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies. Mol Ther 2012; 20:1713-1723.
35. Cressant A, Desmaris N, Verot L, et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J Neurosci 2004;24:10229-10239.
36. Desmaris N, Verot L, Puech JP, et al. Prevention of neuropathology in the mouse model of Hurler syndrome. Ann Neurol 2004;56:68-76.
37. Ellinwood NM, Ausseil J, Desmaris N, et al. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 2011;19:251-259.
38. 1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival. PLoS One 2010; 5:e13468.
39. McCurdy VJ, Johnson AK, Gray-Edwards HL, et al. Sustained normalization of neurological disease after intracranial gene therapy in a feline model. Sci Transl Med 2014;6:231ra248.
40. Janson C, McPhee S, Bilaniuk L, et al. Clinical protocol: Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of as-partoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002;13:1391-1412.
41. McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med 2006;8:577-588.
42. Passini MA, Watson DJ, Vite CH, et al. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of b-glucuronidase-deficient mice. J Virol 2003;77: 7034-7040.
43. 1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery. Mol Ther 2007;15:30-37.
44. Rafi MA, Zhi Rao H, Passini MA, et al. AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. Mol Ther 2005;11:734-744.
45. Fraldi A, Hemsley K, Crawley A, et al. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 2007;16:2693-2702.
46. Liu G, Martins I, Wemmie JA, et al. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J Neurosci 2005;25:9321-9327.
47. Katz ML, Tecedor L, Chen Y, et al. AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease. Sci Transl Med 2015;7:313ra180.
48. Chauhan AN, and Lewis PD. A quantitative study of cell proliferation in ependyma and choroid plexus in the postnatal rat brain. Neuropathol Appl Neurobiol 1979;5:303-309.
49. Haurigot V, Marco S, Ribera A, et al. Whole body correction of mucopolysaccharidosis IIIA by in-tracerebrospinal fluid gene therapy. J Clin Invest 2013;123:3254-3271.
50. Ribera A, Haurigot V, Garcia M, et al. Biochemical, histological and functional correction of mucopolysaccharidosis type IIIB by intra-cerebrospinal fluid gene therapy. Hum Mol Genet 2015;24:2078-2095.
51. Yoon SY, Bagel JH, O'Donnell PA, et al. Clinical Improvement of a-mannosidosis cat following a single cisterna magna infusion of AAV1. Mol Ther 2016;24:26-33.
52. Gurda BL, De Guilhem De Lataillade A, Bell P, et al. Evaluation of AAV-mediated gene therapy for central nervous system disease in canine mucopolysaccharidosis VII. Mol Ther 2016;24: 206-216.
53. Hinderer C, Bell P, Gurda BL, et al. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Mol Ther 2014;22:2018-2027.
54. Elliger SS, Elliger CA, Aguilar CP, et al. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther 1999; 6:1175-1178.
55. Watson G, Bastacky J, Belichenko P, et al. In-trathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice. Gene Ther 2006;13:917-925.
56. Yang B, Li S, Wang H, et al. Global CNS trans-duction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther 2014;22:1299-1309.
57. Miyake N, Miyake K, Asakawa N, et al. Long-term correction of biochemical and neurological abnormalities in MLD mice model by neonatal systemic injection of an AAV serotype 9 vector. Gene Ther 2014;21:427-433.
58. Rafi MA, Rao HZ, Luzi P, et al. Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features. Mol Genet Metab 2015;114:459-466.
59. Naughton BJ, Duncan FJ, Murrey D, et al. Amyloidosis, synucleinopathy, and prion en-cephalopathy in a neuropathic lysosomal storage disease: the CNS-biomarker potential of peripheral blood. PLoS One 2013;8:e80142.
60. Ruzo A, Marco S, Garcia M, et al. Correction of pathological accumulation of glycosaminogly-cans in CNS and peripheral tissues of MPSIIIA mice through systemic AAV9 gene transfer. Hum Gene Ther 2012;23:1237-1246.
61. 1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan. Hum Mol Genet 2015;24:4353-4364.
62. Walia JS, Altaleb N, Bello A, et al. Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates. Mol Ther 2015;23:414-422.
63. Chen YH, Claflin K, Geoghegan JC, et al. Sialic acid deposition impairs the utility of AAV9, but not peptide-modified AAVs for brain gene therapy in a mouse model of lysosomal storage disease. Mol Ther 2012;20:1393-1399.
64. Hardy J, and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991;12: 383-388.
65. Hardy J, Bogdanovic N, Winblad B, et al. Pathways to Alzheimer's disease. J Intern Med 2014;275:296-303.
66. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
67. Miners JS, Barua N, Kehoe PG, et al. Ab-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol 2011;70:944-959.
68. Carty N, Nash KR, Brownlow M, et al. In-tracranial injection of AAV expressing NEP but not IDE reduces amyloid pathology in APP+PS1 transgenic mice. PLoS One 2013;8:e59626.
69. Carty NC, Nash K, Lee D, et al. Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Ab deposits in APP + PS1 transgenic mice. Mol Ther 2008;16:1580-1586.
70. Fukuchi K, Tahara K, Kim HD, et al. Anti-Ab single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. Neurobiol Dis 2006;23:502-511.
71. Zhang YW, Thompson R, Zhang H, et al. APP processing in Alzheimer's disease. Mol Brain 2011;4:3.
72. Weyer SW, Zagrebelsky M, Herrmann U, et al. Comparative analysis of single and combined APP/APLP knockouts reveals reduced spine density in APP-KO mice that is prevented by APPsa expression. Acta Neuropathol Commun 2014;2:36.
73. Endres K, Fahrenholz F. Regulation of a-secretase ADAM10 expression and activity. Exp Brain Res 2012;217:343-352.
74. Fahrenholz F. a-Secretase as a therapeutic target. Curr Alzheimer Res 2007;4:412-417.
75. Deng J, Habib A, Obregon DF, et al. Soluble amyloid precursor protein a inhibits tau phosphory-lation through modulation of GSK3b signaling pathway. J Neurochem 2015;135:630-637.
76. Fol R, Braudeau J, Ludewig S, et al. Viral gene transfer of APPsa rescues synaptic failure in an Alzheimer's disease mouse model. Acta Neuro-pathol 2016;131:247-266.
77. Malkki H. Alzheimer disease: NGF gene therapy activates neurons in the AD patient brain. Nat Rev Neurol 2015;11:548.
78. Kordower JH, Winn SR, Liu YT, et al. The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc Natl Acad Sci USA 1994; 91:10898-10902.
79. Rafii MS, Baumann TL, Bakay RA, et al. A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement 2014;10:571-581.
80. Tuszynski MH, Yang JH, Barba D, et al. Nerve growth factor gene therapy: activation of neu-ronal responses in Alzheimer disease. JAMA Neurol 2015;72:1139-1147.
81. Pascual-Lucas M, Viana da Silva S, Di Scala M, et al. Insulin-like growth factor 2 reverses memory and synaptic deficits in APP transgenic mice. EMBO Mol Med 2014;6:1246-1262.
82. Kiyota T, Ingraham KL, Swan RJ, et al. AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther 2012;19:724-733.
83. Kiyota T, Okuyama S, Swan RJ, et al. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J 2010;24: 3093-3102.
84. Spinney L. Alzheimer's disease: the forgetting gene. Nature 2014;510:26-28.
85. Hudry E, Dashkoff J, Roe AD, et al. Gene transfer of human ApoE isoforms results in differential modulation of amyloid deposition and neuro-toxicity in mouse brain. Sci Transl Med 2013;5:212ra161.
86. Ghribi O. Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J Alzheimers Dis 2008;15:673-684.
87. Hudry E, Van Dam D, Kulik W, et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther 2010;18:44-53.
88. Burlot MA, Braudeau J, Michaelsen-Preusse K, et al. Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like tau pathology. Hum Mol Genet 2015;24:5965-5976.
89. Castle MJ, Turunen HT, Vandenberghe LH, et al. Controlling AAV tropism in the nervous system with natural and engineered capsids. Methods Mol Biol 2016;1382:133-149.
90. Deverman BE, Pravdo PL, Simpson BP, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 2016;34:204-209.
91. Choudhury SR, Fitzpatrick Z, Harris AF, et al. In vivo selection yields AAV-B1 capsid for CNS and muscle gene therapy. Mol Ther 2016 (in press). DOI: 10.1038/mt.2016.84
92. Choudhury SR, Harris AF, Cabral DJ, et al. Widespread central nervous system gene transfer and silencing after systemic delivery of novel AAV-AS vector. Mol Ther 2016;24:726-735.
93. Rocha EM, Smith GA, Park E, et al. Glucocer-ebrosidase gene therapy prevents a-synucleinopathy of midbrain dopamine neurons. Neurobiol Dis 2015; 82:495-503.
94. Oh SM, Chang MY, Song JJ, et al. Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease. EMBO Mol Med 2015;7:510-525.
95. Kearns CM, and Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 1995;672:104-111.
96. Kirik D, Rosenblad C, Burger C, et al. Parkinsonlike neurodegeneration induced by targeted overexpression of a-synuclein in the nigrostriatal system. J Neurosci 2002;22:2780-2791.
97. Sanftner LM, Sommer JM, Suzuki BM, et al. AAV2-mediated gene delivery to monkey puta-men: evaluation of an infusion device and delivery parameters. Exp Neurol 2005;194:476-483.
98. Eslamboli A, Cummings RM, Ridley RM, et al. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol 2003; 184:536-548.
99. Johnston LC, Eberling J, Pivirotto P, et al. Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopa-minergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 2009;20:497-510.
100. Kells AP, Eberling J, Su X, et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 2010;30:9567-9577.
101. Forsayeth JR, Eberling JL, Sanftner LM, et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys. Mol Ther 2006;14:571-577.
102. Gasmi M, Brandon EP, Herzog CD, et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tol-erability of CERE-120 for Parkinson's disease. Neurobiol Dis 2007;27:67-76.
103. Herzog CD, Dass B, Holden JE, et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the do-paminergic nigrostriatal system in aged monkeys. Mov Disord 2007;22:1124-1132.
104. Marks WJ Jr, Baumann TL, and Bartus RT. Long-term safety of patients with Parkinson's disease receiving rAAV2-neurturin (CERE-120) gene transfer. Hum Gene Ther 2016;27:522-527.
105. Herzog CD, Brown L, Kruegel BR, et al. Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neurobiol Dis 2013;58:38-48.
106. Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-1172.
107. Vonsattel JP, and DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998;57:369-384.
108. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985;44:559-577.
109. Kells AP, Henry RA, and Connor B. AAV-BDNF mediated attenuation of quinolinic acid-induced neuropathology and motor function impairment. Gene Ther 2008;15:966-977.
110. Benraiss A, Toner MJ, Xu Q, et al. Sustained mobilization of endogenous neural progenitors delays disease progression in a transgenic model of Huntington's disease. Cell Stem Cell 2013; 12:787-799.
111. McBride JL, During MJ, Wuu J, et al. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol 2003;181:213-223.
112. McBride JL, Ramaswamy S, Gasmi M, et al. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2006;103:9345-9350.
113. Ramaswamy S, McBride JL, Han I, et al. In-trastriatal CERE-120 (AAV-neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis 2009;34: 40-50.
114. Denovan-Wright EM, Attis M, Rodriguez-Lebron E, et al. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice. J Neurosci Res 2008;86:1748-1757.
115. Franich NR, Fitzsimons HL, Fong DM, et al. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther 2008; 16:947-956.
116. Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005;102:5820-5825.
117. Stanek LM, Sardi SP, Mastis B, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum Gene Ther 2014;25: 461-474.
118. McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 2008;105:5868-5873.
119. Garriga-Canut M, Agustin-Pavon C, Herrmann F, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci USA 2012;109: E3136-E3145.
120. Boussicault L, Alves S, Lamaziere A, et al. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Hun-tington's disease. Brain 2016;139:953-970.
121. Kunst CB. Complex genetics of amyotrophic lateral sclerosis. Am J Hum Genet 2004;75:933-947.
122. Higgins CM, Jung C, and Xu Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuo-lation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci 2003;4:16.
123. Kaspar BK, Llado J, Sherkat N, et al. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301:839-842.
124. Lepore AC, Haenggeli C, Gasmi M, et al. In-traparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS. Brain Res 2007;1185: 256-265.
125. Dodge JC, Haidet AM, Yang W, et al. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther 2008;16:1056-1064.
126. Dodge JC, Treleaven CM, Fidler JA, et al. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther 2010;18:2075-2084.
127. Dirren E, Aebischer J, Rochat C, et al. SOD1 silencing in motoneurons or glia rescues neuro-muscular function in ALS mice. Ann Clin Transl Neurol 2015;2:167-184.
128. Ayers JI, Fromholt S, Sinyavskaya O, et al. Widespread and efficient transduction of spinal cord and brain following neonatal AAV injection and potential disease modifying effect in ALS mice. Mol Ther 2015;23:53-62.
129. Aizawa H, Sawada J, Hideyama T, et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol 2010;120:75-84.
130. Yamashita T, Chai HL, Teramoto S, et al. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol Med 2013;5: 1710-1719.
131. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 2010;28:271-274.
132. Passini MA, Bu J, Roskelley EM, et al. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 2010;120:1253-1264.
133. Valori CF, Ning K, Wyles M, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2010;2:35ra42.
134. Dominguez E, Marais T, Chatauret N, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 2011;20:681-693.
135. Nizzardo M, Simone C, Rizzo F, et al. Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model. Sci Adv 2015;1:e1500078.
136. Passini MA, Bu J, Richards AM, et al. Transla-tional fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy. Hum Gene Ther 2014;25:619-630.
137. Galanopoulou AS, Buckmaster PS, Staley KJ, et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012;53:571-582.
138. Richichi C, Lin EJ, Stefanin D, et al. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 2004;24:3051-3059.
139. Foti S, Haberman RP, Samulski RJ, et al. Adeno-associated virus-mediated expression and constitutive secretion of NPY or NPY13-36 suppresses seizure activity in vivo. Gene Ther 2007;14:1534-1536.
140. Noe F, Vaghi V, Balducci C, et al. Anticonvulsant effects and behavioural outcomes of rAAV se-rotype 1 vector-mediated neuropeptide Y over-expression in rat hippocampus. Gene Ther 2010; 17:643-652.
141. Haberman RP, Samulski RJ, and McCown TJ. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 2003;9:1076-1080.
142. Kanter-Schlifke I, Georgievska B, Kirik D, et al. Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol Ther 2007;15: 1106-1113.
143. Theofilas P, Brar S, Stewart KA, et al. Adenosine kinase as a target for therapeutic antisense strategies in epilepsy. Epilepsia 2011;52:589-601.
144. Eaton MJ, Blits B, Ruitenberg MJ, et al. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated over-expression of BDNF in the rat spinal cord. Gene Ther 2002;9:1387-1395.
145. Fischer G, Pan B, Vilceanu D, et al. Sustained relief of neuropathic pain by AAV-targeted expression of CBD3 peptide in rat dorsal root ganglion. Gene Ther 2014;21:44-51.
146. Samad OA, Tan AM, Cheng X, et al. Virus-mediated shRNA knockdown of Na(v)1.3 in rat dorsal root ganglion attenuates nerve injury-induced neuropathic pain. Mol Ther 2013;21:49-56.
147. Tan AM, Samad OA, Dib-Hajj SD, et al. Virus-mediated knockdown of Nav1.3 in dorsal root ganglia of STZ-induced diabetic rats alleviates tactile allodynia. Mol Med 2015;21:544-552.
148. Hirai T, Enomoto M, Kaburagi H, et al. In-trathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hy-peralgesia in a mouse model of peripheral nerve injury. Mol Ther 2014;22:409-419.
149. Mingozzi F, and High KA. Immune responses to AAV in clinical trials. Curr Gene Ther 2011;11: 321-330.
150. Borel F, Kay MA, and Mueller C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol Ther 2014; 22:692-701.
151. Geisler A, Jungmann A, Kurreck J, et al. microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors. Gene Ther 2011;18:199-209.
152. Majowicz A, Maczuga P, Kwikkers KL, et al. Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery. J Gene Med 2013;15:219-232.
153. Qiao C, Yuan Z, Li J, et al. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther 2011;18:403-410.
154. Xie J, Xie Q, Zhang H, et al. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Mol Ther 2011;19:526-535.
155. Doerfler PA, Todd AG, Clement N, et al. Co-packaged AAV9 vectors promote simultaneous immune tolerance and phenotypic correction of Pompe disease. Hum Gene Ther 2016;27:43-59.
156. Hinderer C, Bell P, Louboutin JP, et al. Neonatal systemic AAV induces tolerance to CNS gene therapy in MPS I dogs and nonhuman primates. Mol Ther 2015;23:1298-1307.
157. Mingozzi F, and Buning H. Adeno-associated viral vectors at the frontier between tolerance and immunity. Front Immunol 2015;6:120.
158. Grimm D, Lee JS, Wang L, et al. In vitro and in vivo gene therapy vector evolution via multi-species interbreeding and retargeting of adeno-associated viruses. J Virol 2008;82:5887-5911.
159. Koerber JT, Jang JH, and Schaffer DV. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther 2008; 16:1703-1709.
160. Maheshri N, Koerber JT, Kaspar BK, et al. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 2006;24:198-204.
161. Grieger JC, and Samulski RJ. Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol 2012;507:229-254.
162. LeWitt PA, Rezai AR, Leehey MA, et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011;10:309-319.
163. Mittermeyer G, Christine CW, Rosenbluth KH, et al. Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012;23:377-381.
164. Marks WJ Jr, Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7:400-408.
165. Bartus RT, Baumann TL, Siffert J, et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013;80:1698-1701.
166. 1-gangliosidosis brain. Gene Ther 2009;16:303-308.
167. Sargeant TJ, Wang S, Bradley J, et al. Adeno-associated virus-mediated expression of b-hexosaminidase prevents neuronal loss in the Sandhoff mouse brain. Hum Mol Genet 2011; 20:4371-4380.
168. Lin D, Fantz CR, Levy B, et al. AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol Ther 2005;12:422-430.
169. Macauley SL, Wong AM, Shyng C, et al. An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid li-pofuscinosis. J Neurosci 2014;34:13077-13082.
170. Sondhi D, Scott EC, Chen A, et al. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipo-fuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene. Hum Gene Ther 2014;25:223-239.
171. Passini MA, Dodge JC, Bu J, et al. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid li-pofuscinosis. J Neurosci 2006;26:1334-1342.
172. Winner LK, Beard H, Hassiotis S, et al. A pre-clinical study evaluating AAVrh10-based gene therapy for Sanfilippo syndrome. Hum Gene Ther 2016;27:363-375.
173. Heldermon CD, Ohlemiller KK, Herzog ED, et al. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther 2010;18:873-880.
174. Heldermon CD, Qin EY, Ohlemiller KK, et al. Disease correction by combined neonatal intra-cranial AAV and systemic lentiviral gene therapy in Sanfilippo syndrome type B mice. Gene Ther 2013;20:913-921.
175. Liu G, Chen YH, He X, et al. Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS. Mol Ther 2007;15:242-247.
176. Cearley CN, and Wolfe JH. A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease. J Neurosci 2007;27:9928-9940.
177. Piguet F, Sondhi D, Piraud M, et al. Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice. Hum Gene Ther 2012;23:903-914.
178. Passini MA, Bu J, Fidler JA, et al. Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse. Proc Natl Acad Sci USA 2007;104:9505-9510.
179. Bradbury AM, Cochran JN, McCurdy VJ, et al. Therapeutic response in feline Sandhoff disease despite immunity to intracranial gene therapy. Mol Ther 2013;21:1306-1315.
180. Colle MA, Piguet F, Bertrand L, et al. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum Mol Genet 2010;19:147-158.
181. Zerah M, Piguet F, Colle MA, et al. Intracerebral gene therapy using AAVrh.10-hARSA recombi-nant vector to treat patients with early-onset forms of metachromatic leukodystrophy: pre-clinical feasibility and safety assessments in non-human primates. Hum Gene Ther Clin Dev 2015;26:113-124.
182. Sondhi D, Johnson L, De B, et al. Long term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and non-human primates for the treatment of late infantile neuronal lipofuscinosis. Hum Gene Ther Methods 2012;23:324-335.
183. Ciron C, Cressant A, Roux F, et al. Human a-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and bio-distribution. Hum Gene Ther 2009;20:350-360.
184. Wolf DA, Lenander AW, Nan Z, et al. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of muco-polysaccharidosis type I. Neurobiol Dis 2011; 43:123-133.
185. Fu H, DiRosario J, Kang L, et al. Restoration of central nervous system a-N-acetylglucosaminidase activity and therapeutic benefits in mucopoly-saccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery. J Gene Med 2010;12:624-633.
186. Hironaka K, Yamazaki Y, Hirai Y, et al. Enzyme replacement in the CSF to treat meta-chromatic leukodystrophy in mouse model using single intracerebroventricular injection of self-complementary AAV1 vector. Sci Rep 2015;5: 13104.
187. Yamazaki Y, Hirai Y, Miyake K, et al. Targeted gene transfer into ependymal cells through in-traventricular injection of AAV1 vector and long-term enzyme replacement via the CSF. Sci Rep 2014;4:5506.
188. Spampanato C, De Leonibus E, Dama P, et al. Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder. Mol Ther 2011;19:860-869.
189. Rafi MA, Rao HZ, Luzi P, et al. Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol Ther 2012;20:2031-2042.
190. Polito VA, and Cosma MP. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice. Am J Hum Genet 2009;85:296-301.
191. Jung SC, Park ES, Choi EN, et al. Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2/8 vectormediated gene therapy. Mol Cells 2010;30:13-18.
192. Duncan FJ, Naughton BJ, Zaraspe K, et al. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice. Mol Ther 2015; 23:638-647.
193. McCarty DM, DiRosario J, Gulaid K, et al. Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice. Gene Ther 2009; 16:1340-1352.
194. Hinderer C, Bell P, Gurda BL, et al. Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I. Proc Natl Acad Sci USA 2014;111:14894-14899.
195. Murrey DA, Naughton BJ, Duncan FJ, et al. Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysacchar-idosis IIIB: toxicology, biodistribution, and im-munological assessments in primates. Hum Gene Ther Clin Dev 2014;25:72-84.
196. Rockwell HE, McCurdy VJ, Eaton SC, et al. AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system. ASN Neuro 2015;7.
197. Gray-Edwards HL, Brunson BL, Holland M, et al. Mucopolysaccharidosis-like phenotype in feline Sandhoff disease and partial correction after AAV gene therapy. Mol Genet Metab 2015;116: 80-87.
198. Fu H, Kang L, Jennings JS, et al. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther 2007;14:1065-1077.
199. Elliger SS, Elliger CA, Lang C, et al. Enhanced secretion and uptake of b-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. Mol Ther 2002;5:617-626.
200. Kiyota T, Yamamoto M, Schroder B, et al. AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, b-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther 2009;17:803-809.
201. Saal KA, Koch JC, Tatenhorst L, et al. AAV. shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo. Neurobiol Dis 2015;73:150-162.
202. Alto LT, Chen X, Ruhn KA, et al. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease. PLoS One 2014;9:e96544.
203. Boudreau RL, McBride JL, Martins I, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 2009;17:1053-1063.
204. Connor B, Sun Y, von Hieber D, et al. AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington's disease. Gene Ther 2016;23:283-295.
205. Klein RL, Hirko AC, Meyers CA, et al. NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res 2000;875:144-151.
206. McBride JL, Pitzer MR, Boudreau RL, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Hun-tington's disease. Mol Ther 2011;19:2152-2162.
207. Emborg ME, Carbon M, Holden JE, et al. Sub-thalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 2007;27:501-509.
208. Stoica L, Todeasa SH, Cabrera GT, et al. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol 2016;79:687-700.
209. Wang H, Yang B, Qiu L, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet 2014;23:668-681.
210. Mussche S, Devreese B, Nagabhushan Kalburgi S, et al. Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum Gene Ther 2013;24:209-219.
211. G93A mice and nonhuman primates. Hum Gene Ther 2016;27:19-31.
212. Dufour BD, Smith CA, Clark RL, et al. Intrajugular vein delivery of AAV9-RNAi prevents neuro-pathological changes and weight loss in Hun-tington's disease mice. Mol Ther 2014;22:797-810.
213. Franz CK, Federici T, Yang J, et al. Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis 2009;33:473-481.
214. Sorensen AT, Nikitidou L, Ledri M, et al. Hip-pocampal NPY gene transfer attenuates seizures without affecting epilepsy-induced impairment of LTP. Exp Neurol 2009;215:328-333.
215. Noe F, Pool AH, Nissinen J, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008;131:1506-1515.
216. Haberman R, Criswell H, Snowdy S, et al. Therapeutic liabilities of in vivo viral vector tro-pism: adeno-associated virus vectors, NMDAR1 antisense, and focal seizure sensitivity. Mol Ther 2002;6:495-500.
217. Storek B, Reinhardt M, Wang C, et al. Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc Natl Acad Sci USA 2008;105:1055-1060.